Diagnostic Medical Systems (XPAR:ALDMS) ROCE %: 0.00% (As of Dec. 2025)


XPAR:ALDMS Diagnostic Medical Systems XPAR:ALDMS
68 GF Score
Price €1.25
GF Value €1.14
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Diagnostic Medical Systems ROCE %?

Diagnostic Medical Systems XPAR:ALDMS -1.57% 68 ROCE % is 0.00% as of Dec. 2025. GuruFocus rates XPAR:ALDMS with a GF Score™ of 68/100 and a GF Value™ of €1.14 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Diagnostic Medical Systems's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.00%.

Diagnostic Medical Systems  (XPAR:ALDMS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Diagnostic Medical Systems ROCE % Related Terms

Diagnostic Medical Systems ROCE % Historical Data

* Premium members only.

The historical data trend for Diagnostic Medical Systems's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnostic Medical Systems ROCE % Chart

Diagnostic Medical Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.78 -21.11 -32.01 -6.28 2.70

Diagnostic Medical Systems Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.00 -92.99 -8.20 -5.07 0.00
XPAR:ALDMS
68GF Score
Diagnostic Medical Systems XPAR:ALDMS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnostic Medical Systems ROCE % Calculation

Diagnostic Medical Systems's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=0.881/( ( (53.949 - 23.497) + (62.517 - 27.623) )/ 2 )
=0.881/( (30.452+34.894)/ 2 )
=0.881/32.673
=2.70 %

Diagnostic Medical Systems's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Dec. 2024 )(Q: Dec. 2025 )
=0/( ( (53.949 - 23.497) + (62.517 - 27.623) )/ 2 )
=0/( ( 30.452 + 34.894 )/ 2 )
=0/32.673
=0.00 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Diagnostic Medical Systems (XPAR:ALDMS) has a ROCE % of 0.00% as of Dec. 2025.
Is Diagnostic Medical Systems' ROCE % too high?
Diagnostic Medical Systems' current ROCE % is 0.00%. Overall, Diagnostic Medical Systems has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diagnostic Medical Systems' ROCE % compare to ABT and SYK?
Diagnostic Medical Systems' ROCE % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostic Medical Systems's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostic Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Diagnostic Medical Systems (XPAR:ALDMS) is currently considered Fairly Valued. The stock's GF Value™ is €1.14, compared to a current price of €1.25 — trading 9.6% above its estimated fair value. The current ROCE % is 0.00%. Diagnostic Medical Systems' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Diagnostic Medical Systems (XPAR:ALDMS), the current ROCE % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diagnostic Medical Systems (XPAR:ALDMS) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnostic Medical Systems stock appears to be overvalued. The current stock price of €1.25 is trading 9.6% above its estimated GF Value™ of €1.14. GuruFocus considers Diagnostic Medical Systems to be Fairly Valued.

Key valuation signals for XPAR:ALDMS:

  • ROCE %: 0.00%
  • GF Value™: €1.14 vs. price of €1.25 (9.6% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALDMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diagnostic Medical Systems Business Description

Other Exchanges 0RIA:UKDMS1:Germany
Address 9 Avenue du Canal Philippe, Gallargues le Montueux, FRA, FR-30660
Diagnostic Medical Systems is France's company engaged in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: Radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; and the Development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine.
68GF Score

Get the complete analysis for XPAR:ALDMS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.25
Price
€1.14
GF Value